Correction to "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?"

Hee Sun Baek, Min Hyun Cho

Open source

DOI
10.3339/ckd.23.021.c1
Published
2026-01-12
Container
Childhood Kidney Diseases
Publisher
Korean Society of Pediatric Nephrology
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3339/ckd.23.021.c1,
  title = {Correction to "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?"},
  author = {Hee Sun Baek and Min Hyun Cho},
  year = {2026},
  journal = {Childhood Kidney Diseases},
  doi = {10.3339/ckd.23.021.c1},
  url = {https://doi.org/10.3339/ckd.23.021.c1}
}

RIS

TY  - JOUR
TI  - Correction to "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?"
AU  - Hee Sun Baek
AU  - Min Hyun Cho
PY  - 2026
JO  - Childhood Kidney Diseases
DO  - 10.3339/ckd.23.021.c1
UR  - https://doi.org/10.3339/ckd.23.021.c1
ER  - 

APA

Baek, H. S., & Cho, M. H. (2026). Correction to "Tolvaptan: a possible preemptive treatment option in children with autosomal dominant polycystic kidney disease?". Childhood Kidney Diseases. https://doi.org/10.3339/ckd.23.021.c1

Source records